Active Ingredient History

NOW
  • Now
Lacosamide is an anticonvulsant that is FDA approved for the treatment of partial-onset seizures. The precise mechanism by which lacosamide exerts its antiepileptic effects in humans remains to be fully elucidated. In vitro electrophysiological studies have shown that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing Common adverse reactions include diplopia, headache, dizziness, nausea. Patients with renal or hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 may have a significant increase in exposure to Lacosamide tablets.   NCATS

  • SMILES: COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
  • InChIKey: VPPJLAIAVCUEMN-GFCCVEGCSA-N
  • Mol. Mass: 250.2936
  • ALogP: 0.45
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

Australia

$1.0882 - $47.8903

United States

$1.2004 - $167.6167
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

2-(acetylamino)-3-methoxy-n-(phenylmethyl)-, (2r)- | add-234037 | add-243037 | erlosamide | ertosamide | harkoseride | lacosamide | lacosmide | lasosamide | n-benzyl-2-acetamido-3-methoxypropionamide | n-benzyl-acmeoprnh2 | spm927 | spm-927 | spm 929 | vimpat

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue